Haisco Pharmaceutical Group (002653.SZ) innovative drug HSK44459 tablets clinical trial application accepted

Haisco Pharmaceutical Group (002653.SZ) announced that the company recently received a notice of acceptance from the National Medical Products Administration for the registration clinical trial application for the innovative drug HSK44459 for domestic production. The indication for this drug is for the treatment of Behcet's disease. Behcet's disease, also known as Behcet's disease, is a chronic, recurrent autoimmune/inflammatory disease with vasculitis as the underlying pathological change. It is characterized by recurrent oral ulcers, genital ulcers, uveitis, and skin lesions, and can also affect peripheral blood vessels, heart, nervous system, gastrointestinal tract, joints, lungs, kidneys and other organs. HSK44459 is a new drug developed independently by the company with proprietary rights for the treatment of Behcet's disease.